As a 501(c)(3) nonprofit, we depend almost entirely on donations from people like you.
We really need your help to continue this work! Please consider making a donation.
Subscribe here and join over 13,000 subscribers to our free weekly newsletter

Clinical trials test potential of hallucinogenic drugs to help patients with terminal illnesses
Key Excerpts from Article on Website of The Guardian (One of the U.K.'s leading newspapers)


The Guardian (One of the U.K.'s leading newspapers), August 12, 2008
Posted: August 23rd, 2008
http://www.guardian.co.uk/science/2008/aug/12/medicalresearc...

Scientists are exploring the use of psychedelic drugs such as LSD to treat a range of ailments from depression to cluster headaches and obsessive compulsive disorder. The first clinical trial using LSD since the 1970s began in Switzerland in June. It aims to use "psychedelic psychotherapy" to help patients with terminal illnesses come to terms with their imminent mortality and so improve their quality of life. Another psychedelic substance, psilocybin, has shown promising results in trials for treating symptoms of terminal cancer patients. In the Swiss trial eight subjects will receive a dose of 200 microgrammes of LSD. This is enough to induce a powerful psychedelic experience. A further four subjects will receive a dose of 20 microgrammes. Every participant will know they have received some LSD, but neither the subjects nor the researchers observing them will know for certain who received the full dose. During the course of therapy researchers will assess the patients' anxiety levels, quality of life and pain levels. Before hallucinogenic drugs became popular with the counter culture, they were at the forefront of brain science. They were used to help scientists understand the nature of consciousness and how the brain works and as treatments for a range of conditions. Dr Rick Doblin is president of the Multidisciplinary Association for Psychedelic Studies (MAPS) in California, a nonprofit organisation which funds clinical studies into psychedelic drugs, including the Swiss LSD trial. "These drugs, these experiences are not for the mystic who wants to sit on the mountain top and meditate. They are not for the counter-culture rebel. They are for everybody," he said.


Top Inspiring News Articles


Top Inspiring News Articles from Years Past